A Phase 3 interventional study of Liraglutide and Placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 33 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-04-27.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 14th largest by enrollment, is one of 12 that started in 2016, is one of 17 in phase 3, and was the 29th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 12 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 62nd largest by enrollment of the 166 interventional ones that give a count, is one of 9 that started in 2016, is one of 62 in phase 3, and was the 23rd registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 251 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Liraglutide
Drug: Placebo
Administered once daily subcutaneously (s.c., under the skin)
Administered once daily subcutaneously (s.c., under the skin)
Change in BMI SDS (Week 0, Week 56)
Change from baseline (week 0) in BMI SDS was evaluated at week 56. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the world health organisation (WHO) Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation. Results are based on both participants who completed the week 0-56 trial period and participants who prematurely discontinued the trial product but attended the follow-up visit at 56.
Time frame: Week 0, week 56
Percent of Subjects Achieving ≥5% Reduction in Baseline BMI
Participants achieving more than or equal to 5% reduction in their baseline (week 0) BMI was evaluated at weeks 30, 56 and 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
Time frame: Weeks 30, 56 and 82
Percent of Subjects Achieving ≥10% Reduction in Baseline BMI
Participants achieving more than or equal to 10% reduction in their baseline (week 0) BMI was evaluated at weeks 30, 56 and 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
Time frame: Weeks 30, 56 and 82
Change in BMI SDS ((Week 0, Week 30); (Week 0, Week 82); (Week 56, Week 82))
Change in BMI SDS was evaluated from baseline (week 0) to weeks 30 and 82, and from week 56 to week 82. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation. Results are based on both participants who completed the trial period, week 0-30 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30 or 82, respectively.
Time frame: (Week 0, week 30); (Week 0, week 82); (Week 56, week 82)
Change in BMI
Change in BMI was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Body Weight (kg)
Change in body weight (kg) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Body Weight (%)
Relative change in body weight (kg) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Body Weight (lb)
Body weight was not analysed in pounds (lb). It was analysed for standard unit, 'kg' only.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Waist Circumference
Change in waist circumference was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Waist-to-hip Circumference Ratio
Change in waist-to-hip circumference ratio was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in hsCRP
Change in high sensitivity C reactive protein (hsCRP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting Lipid: Total Cholesterol (Ratio to Baseline)
Change in total cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting Lipid: LDL-cholesterol (Ratio to Baseline)
Change in low density lipoprotein (LDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting Lipid: HDL-cholesterol (Ratio to Baseline)
Change in high density lipoprotein (HDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting Lipid: Non-HDL Cholesterol (Ratio to Baseline)
Change in non-HDL cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting Lipid: VLDL Cholesterol (Ratio to Baseline)
Change in very low density lipoprotein (VLDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting Lipid: Triglycerides (Ratio to Baseline)
Change in triglycerides from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting Lipid: FFA (Ratio to Baseline)
Change in free fatty acids (FFA) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Systolic and Diastolic Blood Pressure
Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in HbA1c
Change in glycosylated haemoglobin (HbA1c) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in FPG
Change in fasting plasma glucose (FPG) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed treatment for the corresponding treatment period (week 0-30, week 0-56 or week 0-82).
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting Insulin (Ratio to Baseline)
Change in fasting insulin from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Fasting C-peptide (Ratio to Baseline)
Change in fasting C-peptide from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Glycaemic Category
Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes (T2DM)" at baseline (weeks -2), and weeks 30, 56 and 82 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes (T2DM): FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: Week -2, week 30, week 56 and week 82
Change in HOMA-B (Ratio to Baseline)
Change in homeostasis model assessment of beta-cell function (HOMA-B) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5). Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in HOMA-IR (Ratio to Baseline)
Change in homeostasis model assessment of insulin resistance (HOMA-IR) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting insulin \[mU/L\] x FPG \[mmol/L\]/ 22.5. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in IWQOL-Kids
Change in Impact of Weight on Quality of Life-Kids (IWQOL-Kids) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. The IWQOL-Kids is a 27-item measure of weight-related quality of life. There are four domain scores (Physical Comfort, Body Esteem, Social Life and Family Life) and a total score. Scores for all domains and total score range from 0-100, with higher scores representing better health-related quality of life. IWQOL-kids data at week 82 was not collected, thus could not be evaluated. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in BMI SDS (%)
Relative change in BMI SDS was evaluated from baseline (week 0) to weeks 30 and 56. Results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.
Time frame: (Week 0, week 30); (Week 0, week 56)
Change in Nutritional Compliance
This outcome measure presents "nutritional compliance results" recorded at baseline (week 0), week 30 and week 56. Nutritional compliance was recorded on a 0 to 10 numeric rating scale, with higher scores representing better compliance. Week 30 and 56 results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.
Time frame: Week 0, week 30 and week 56
Number of Treatment Emergent Adverse Events
A treatment emergent adverse event (TEAE) was defined as an event that occurred in the "on-treatment" period. 'On-treatment' period: Events with onset date between the first day of trial product administration and any of the following date, whichever came first: 1) 14 days after the last day on trial product, or 2) follow-up visit (week 58) for participants who discontinued trial product, or 3) last study visit (participants withdrawn without follow-up visit).
Time frame: Week 0-56 + 14 days
Number of Treatment Emergent Hypoglycaemic Episodes (ADA/ISPAD Classification)
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia episodes were recorded as per international society for pediatric and adolescent diabetes (ISPAD) definition. And the following presented hypoglycaemia episodes were recorded as per American Diabetes Association (ADA) definition: asymptomatic hypoglycaemia, documented symptomatic hypoglycaemia, pseudo-hypoglycaemia and probable symptomatic hypoglycaemia.
Time frame: Week 0-56 + 14 days
Number of Treatment Emergent Hypoglycaemic Episodes (Novo Nordisk/ISPAD Classification)
Severe hypoglycaemia episodes were recorded as per the ISPAD definition. And the following presented hypoglycaemia episodes were recorded as per Novo Nordisk definition: Symptomatic BG-confirmed: An episode that is blood glucose (BG) confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Asymptomatic BG-confirmed: An episode that is BG-confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. 4) Severe or BG-confirmed symptomatic: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. 5) BG-confirmed: An episode that is BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. 6) Severe or BG-confirmed: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia.
Time frame: Week 0-56 + 14 days
Occurrence of Anti-liraglutide Antibodies
This outcome measure is only applicable for the liraglutide 3.0 mg treatment arm. Number of participants who measured with anti-liraglutide binding antibodies at weeks 0, 30, 56, 58, 70 and 82 are presented.
Time frame: Weeks 0, 30, 56, 58, 70 and 82
Change in Pulse
Change in pulse was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in ECG
This outcome measure presents number of subjects with electrocardiogram findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" recorded at baseline (week -14), week 30 and week 56. These findings were categorised by the investigator. Electrocardiogram (ECG) data at week 82 was not collected, thus could not be evaluated. Week 30 and 56 results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.
Time frame: Week -14, week 30, week 56 and week 82
Change in Haematology: Haemoglobin
Change in haemoglobin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Haematology: Haematocrit
Change in haematocrit was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Haematology: Thrombocytes, Leucocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes and Monocytes
Change in haematological parameters, "thrombocytes, leucocytes, eosinophils, neutrophils, basophils, lymphocytes and monocytes" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Haematology: Erythrocytes
Change in erythrocytes was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Biochemistry: Creatinine and Bilirubin (Total)
Change in creatinine and bilirubin (total) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Biochemistry: Creatinine Kinase, Amylase, Lipase, ALT, AST and ALP
Change in biochemistry parameters, "creatinine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Biochemistry: Urea (BUN), Sodium, Potassium, Calcium Total and Calcium Albumin-corrected
Change in biochemistry parameters, "urea (blood urea nitrogen \[BUN\]), sodium, potassium, calcium total and calcium (Ca) albumin-corrected" was evaluated from baseline (week \[Wk\] 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Biochemistry: Albumin
Change in albumin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Biochemistry: CEA
Change in carcinoembryonic antigen (CEA) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Hormone Level: Calcitonin
Change in calcitonin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Hormone Level: TSH and Prolactin
Change in hormone levels, "thyroid stimulating hormone (TSH) and prolactin" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Hormone Level: Free T4 and ACTH
Change in hormone levels, "thyroxine (T4) and adrenocorticotropic hormone (ACTH)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Hormone Level: IGF-1 and Cortisol
Change in hormone levels, "insulin-like growth factor-1 (IGF-1) and cortisol" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Hormone Level: DHEAS
Change in dehydroepiandrosterone sulfate (DHEAS) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Hormone Level: LH and FSH
Change in hormone levels, "luteinising hormone (LH) and follicle stimulating hormone (FSH)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Hormone Level: Estradiol (Females)
Change in estradiol (only for female) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Hormone Level: Testosterone (Males)
This outcome measure presents "testosterone (only for males) results" for baseline (week 0), week 30, week 56 and week 82. ADVIA Centaur Testosterone (TSTO) assay was used for the evaluation of testosterone hormone. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: Week 0, week 30, week 56 and week 82
Change in NTX1
Change in type I collagen N-telopeptide (NTX1) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are presented in "nmol bone collagen equivalents (BCE)/L". Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in CTX1
Change in type I collagen C-telopeptide (CTX1) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in P1NP
Change in procollagen 1 N-terminal propeptide (P1NP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Alkaline Phosphatase (Bone)
Change in alkaline phosphatase (bone specific) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Pubertal Status
This outcome measure presents "pubertal status results" which is based on Tanner staging (Tanner stage 2-5), recorded at baseline (week 0), week 30, week 56 and week 82. Results are presented for the following categories: 1) For female: breast development and pubic hair development (by Tanner staging). 2) For male: penis development and pubic hair development (by Tanner staging). Each category shows number of participants in stages 2 to 5, where stage 2 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult". Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in Physical Examination
This outcome measure presents number of subjects with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 30, week 56 and week 82. These findings were categorised by the investigator. Results include examination of: "general appearance"; "head, ears, eyes, nose, throat, neck"; "respiratory system"; "cardiovascular system (CVS)"; "gastrointestinal (GI) system including mouth"; "musculoskeletal system"; "central nervous system (CNS) and peripheral nervous system (PNS)"; "skin"; "thyroid gland" and "lymph node palpation". Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: Week 0, week 30, week 56 and week 82
Change in Height SDS
Change in height standard deviation score (SDS) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in C-SSRS
This outcome measure presents number of subjects with "suicidal ideation or suicidal behaviour on the Columbia Suicidality Severity Rating Scale (C-SSRS)" assessed at baseline (week 0), week 30, week 56 and week 82. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Change in PHQ-9
Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
This trial was conducted at 32 sites in 5 countries: Belgium (6 sites), Sweden (4 sites), Russia (8 sites), Mexico (2 sites) and the United States of America (USA - 12 sites). Additionally, 1 site in the USA was approved by the independent review board, but did not randomise any participant.
| Milestone | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Started | 125 | 126 |
| Full analysis set | 125 | 126 |
| Safety analysis set | 125 | 126 |
| Completed | 112 | 103 |
| Not completed | 13 | 23 |
| Withdrew: Lost to follow-up | 3 | 6 |
| Withdrew: Withdrawal by subject | 5 | 15 |
| Withdrew: Withdrawal by parent/guardian | 2 | 1 |
| Withdrew: Other | 3 | 1 |
Change from baseline (week 0) in BMI SDS was evaluated at week 56. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the world health organisation (WHO) Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation. Results are based on both participants who completed the week 0-56 trial period and participants who prematurely discontinued the trial product but attended the follow-up visit at 56.
| SDS score | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in BMI SDS (Week 0, Week 56) | -0.25 ± 0.51 | -0.02 ± 0.54 |
Participants achieving more than or equal to 5% reduction in their baseline (week 0) BMI was evaluated at weeks 30, 56 and 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Week 30 (Yes) | 46.2 | 14.7 |
| Week 30 (No) | 53.8 | 85.3 |
| Week 56 (Yes) | 45.1 | 19.0 |
| Week 56 (No) | 54.9 | 81.0 |
| Week 82 (Yes) | 29.5 | 18.6 |
| Week 82 (No) | 70.5 | 81.4 |
Participants achieving more than or equal to 10% reduction in their baseline (week 0) BMI was evaluated at weeks 30, 56 and 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Week 30 (Yes) | 24.4 | 5.2 |
| Week 30 (No) | 75.6 | 94.8 |
| Week 56 (Yes) | 29.2 | 8.6 |
| Week 56 (No) | 70.8 | 91.4 |
| Week 82 (Yes) | 18.8 | 10.8 |
| Week 82 (No) | 81.3 | 89.2 |
Change in BMI SDS was evaluated from baseline (week 0) to weeks 30 and 82, and from week 56 to week 82. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation. Results are based on both participants who completed the trial period, week 0-30 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30 or 82, respectively.
| SDS score | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -0.26 ± 0.34 | -0.04 ± 0.33 |
| Change from week 0 to week 82 | -0.06 ± 0.53 | 0.07 ± 0.66 |
| Change from week 56 to week 82 | 0.22 ± 0.28 | 0.08 ± 0.27 |
Change in BMI was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
| kg/m^2 | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -1.8 ± 2.1 | -0.2 ± 2.2 |
| Change from week 0 to week 56 | -1.6 ± 3.1 | 0.1 ± 3.4 |
| Change from week 56 to week 82 | 1.5 ± 1.7 | 0.7 ± 1.7 |
Change in body weight (kg) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
| kg | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -3.9 ± 6.1 | 0.4 ± 6.6 |
| Change from week 0 to week 56 | -2.7 ± 9.1 | 2.1 ± 10.2 |
| Change from week 56 to week 82 | 4.7 ± 4.6 | 2.4 ± 4.9 |
Relative change in body weight (kg) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
| Percentage change | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -4.3 ± 6.5 | 0.4 ± 6.2 |
| Change from week 0 to week 56 | -3.2 ± 9.4 | 2.2 ± 9.5 |
| Change from week 56 to week 82 | 5.3 ± 5.7 | 2.3 ± 4.9 |
Body weight was not analysed in pounds (lb). It was analysed for standard unit, 'kg' only.
No measurements were reported for this outcome.
Change in waist circumference was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| cm | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -4.63 ± 6.24 | -2.01 ± 5.94 |
| Change from week 0 to week 56 | -5.12 ± 7.87 | -1.51 ± 8.20 |
| Change from week 56 to week 82 | 3.58 ± 4.30 | 1.24 ± 5.60 |
Change in waist-to-hip circumference ratio was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -0.015 ± 0.042 | -0.018 ± 0.042 |
| Change from week 0 to week 56 | -0.022 ± 0.053 | -0.023 ± 0.051 |
| Change from week 56 to week 82 | 0.010 ± 0.031 | 0.003 ± 0.049 |
Change in high sensitivity C reactive protein (hsCRP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| mg/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -0.22 ± 5.04 | -0.56 ± 4.68 |
| Change from week 0 to week 56 | -0.25 ± 4.54 | -0.14 ± 3.44 |
| Change from week 56 to week 82 | 1.51 ± 7.61 | 1.00 ± 4.22 |
Change in total cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of total cholesterol | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 1.00 ± 12.8 | 0.98 ± 13.0 |
| Change from week 0 to week 56 | 1.00 ± 14.2 | 1.00 ± 13.0 |
| Change from week 56 to week 82 | 1.02 ± 14.7 | 1.02 ± 14.9 |
Change in low density lipoprotein (LDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of LDL-cholesterol | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 1.00 ± 19.8 | 1.00 ± 26.1 |
| Change from week 0 to week 56 | 0.99 ± 21.8 | 1.02 ± 23.6 |
| Change from week 56 to week 82 | 1.03 ± 22.5 | 1.04 ± 20.6 |
Change in high density lipoprotein (HDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of HDL-cholesterol | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 1.04 ± 15.3 | 1.01 ± 20.5 |
| Change from week 0 to week 56 | 1.04 ± 17.4 | 1.02 ± 18.9 |
| Change from week 56 to week 82 | 0.99 ± 15.8 | 1.00 ± 15.2 |
Change in non-HDL cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of non-HDL cholesterol | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.98 ± 16.8 | 0.97 ± 18.0 |
| Change from week 0 to week 56 | 0.98 ± 18.4 | 0.99 ± 16.7 |
| Change from week 56 to week 82 | 1.03 ± 19.8 | 1.02 ± 18.6 |
Change in very low density lipoprotein (VLDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of VLDL cholesterol | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.91 ± 36.8 | 0.90 ± 42.7 |
| Change from week 0 to week 56 | 0.92 ± 43.7 | 0.93 ± 34.6 |
| Change from week 56 to week 82 | 1.04 ± 51.0 | 0.97 ± 34.1 |
Change in triglycerides from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of triglycerides | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.91 ± 36.9 | 0.91 ± 42.9 |
| Change from week 0 to week 56 | 0.92 ± 43.2 | 0.93 ± 34.4 |
| Change from week 56 to week 82 | 1.04 ± 50.4 | 0.97 ± 34.0 |
Change in free fatty acids (FFA) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of FFA | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.96 ± 57.7 | 0.83 ± 56.4 |
| Change from week 0 to week 56 | 1.00 ± 48.9 | 0.95 ± 50.8 |
| Change from week 56 to week 82 | 0.99 ± 55.2 | 0.94 ± 38.0 |
Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| mmHg | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| SBP: Change from week 0 to week 30 | -2 ± 9 | -1 ± 10 |
| SBP: Change from week 0 to week 56 | -2 ± 10 | 1 ± 10 |
| SBP: Change from week 56 to week 82 | 2 ± 9 | 1 ± 10 |
| DBP: Change from week 0 to week 30 | -0 ± 8 | -1 ± 10 |
| DBP: Change from week 0 to week 56 | 1 ± 9 | -1 ± 9 |
| DBP: Change from week 56 to week 82 | 2 ± 8 | 2 ± 7 |
Change in glycosylated haemoglobin (HbA1c) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Percentage of HbA1c | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -0.1 ± 0.3 | -0.0 ± 0.3 |
| Change from week 0 to week 56 | -0.1 ± 0.3 | -0.0 ± 0.2 |
| Change from week 56 to week 82 | 0.1 ± 0.2 | 0.1 ± 0.3 |
Change in fasting plasma glucose (FPG) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed treatment for the corresponding treatment period (week 0-30, week 0-56 or week 0-82).
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -0.2 ± 0.4 | -0.0 ± 0.5 |
| Change from week 0 to week 56 | -0.1 ± 0.5 | -0.0 ± 0.6 |
| Change from week 56 to week 82 | 0.1 ± 0.6 | 0.1 ± 0.5 |
Change in fasting insulin from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of fasting insulin | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 1.13 ± 70.9 | 1.14 ± 53.7 |
| Change from week 0 to week 56 | 1.06 ± 69.4 | 1.10 ± 73.8 |
| Change from week 56 to week 82 | 1.00 ± 60.9 | 1.08 ± 55.2 |
Change in fasting C-peptide from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of fasting C-peptide | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 1.12 ± 42.6 | 1.04 ± 35.1 |
| Change from week 0 to week 56 | 0.98 ± 44.9 | 0.97 ± 47.4 |
| Change from week 56 to week 82 | 0.92 ± 43.6 | 0.94 ± 32.9 |
Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes (T2DM)" at baseline (weeks -2), and weeks 30, 56 and 82 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes (T2DM): FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Week -2 — Normoglycaemia | 93 | 93 |
| Week -2 — Pre-diabetes | 31 | 32 |
| Week -2 — Type 2 diabetes | 1 | 1 |
| Week 30 — Normoglycaemia | 95 | 86 |
| Week 30 — Pre-diabetes | 19 | 29 |
| Week 30 — Type 2 diabetes | 2 | 1 |
| Week 56 — Normoglycaemia | 86 | 75 |
| Week 56 — Pre-diabetes | 17 | 24 |
| Week 56 — Type 2 diabetes | 2 | 2 |
| Week 82 — Normoglycaemia | 79 | 65 |
| Week 82 — Pre-diabetes | 20 | 30 |
| Week 82 — Type 2 diabetes | 1 | 4 |
Change in homeostasis model assessment of beta-cell function (HOMA-B) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5). Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of HOMA-B | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 1.32 ± 70.8 | 1.17 ± 59.5 |
| Change from week 0 to week 56 | 1.13 ± 67.0 | 1.11 ± 58.0 |
| Change from week 56 to week 82 | 0.92 ± 65.9 | 1.02 ± 50.2 |
Change in homeostasis model assessment of insulin resistance (HOMA-IR) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting insulin \[mU/L\] x FPG \[mmol/L\]/ 22.5. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Ratio of HOMA-IR | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 1.08 ± 75.2 | 1.14 ± 55.6 |
| Change from week 0 to week 56 | 1.04 ± 75.3 | 1.09 ± 80.0 |
| Change from week 56 to week 82 | 1.03 ± 64.2 | 1.11 ± 60.5 |
Change in Impact of Weight on Quality of Life-Kids (IWQOL-Kids) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. The IWQOL-Kids is a 27-item measure of weight-related quality of life. There are four domain scores (Physical Comfort, Body Esteem, Social Life and Family Life) and a total score. Scores for all domains and total score range from 0-100, with higher scores representing better health-related quality of life. IWQOL-kids data at week 82 was not collected, thus could not be evaluated. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Scores on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Body Esteem: Change from week 0 to week 30 | 10.62 ± 19.88 | 6.73 ± 26.87 |
| Body Esteem: Change from week 0 to week 56 | 13.33 ± 19.47 | 13.24 ± 22.72 |
| Family Relation: Change from week 0 to week 30 | 2.53 ± 9.66 | -2.19 ± 17.53 |
| Family Relation: Change from week 0 to week 56 | 1.44 ± 14.31 | 0.97 ± 5.61 |
| Physical Function: Change from week 0 to week 30 | 3.94 ± 15.34 | 0.43 ± 22.02 |
| Physical Function: Change from week 0 to week 56 | 6.17 ± 15.44 | 3.32 ± 16.60 |
| Social Life: Change from week 0 to week 30 | 5.32 ± 10.56 | 1.76 ± 21.98 |
| Social Life: Change from week 0 to week 56 | 5.97 ± 19.48 | 6.06 ± 14.04 |
| Total: Change from week 0 to week 30 | 6.16 ± 11.04 | 2.24 ± 19.69 |
| Total: Change from week 0 to week 56 | 7.46 ± 13.70 | 6.72 ± 11.62 |
Relative change in BMI SDS was evaluated from baseline (week 0) to weeks 30 and 56. Results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.
| Percentage change | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -8.73 ± 1.05 | -1.70 ± 1.07 |
| Change from week 0 to week 56 | -8.32 ± 1.68 | -0.68 ± 1.74 |
This outcome measure presents "nutritional compliance results" recorded at baseline (week 0), week 30 and week 56. Nutritional compliance was recorded on a 0 to 10 numeric rating scale, with higher scores representing better compliance. Week 30 and 56 results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Week 0 | 7.10 ± 1.74 | 7.07 ± 1.69 |
| Week 30 | 6.74 ± 2.08 | 6.51 ± 1.91 |
| Week 56 | 6.87 ± 1.87 | 6.45 ± 1.84 |
A treatment emergent adverse event (TEAE) was defined as an event that occurred in the "on-treatment" period. 'On-treatment' period: Events with onset date between the first day of trial product administration and any of the following date, whichever came first: 1) 14 days after the last day on trial product, or 2) follow-up visit (week 58) for participants who discontinued trial product, or 3) last study visit (participants withdrawn without follow-up visit).
| Events | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Number of Treatment Emergent Adverse Events | 777 | 627 |
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia episodes were recorded as per international society for pediatric and adolescent diabetes (ISPAD) definition. And the following presented hypoglycaemia episodes were recorded as per American Diabetes Association (ADA) definition: asymptomatic hypoglycaemia, documented symptomatic hypoglycaemia, pseudo-hypoglycaemia and probable symptomatic hypoglycaemia.
| Episodes | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Severe hypoglycaemia | 0 | 0 |
| Asymptomatic hypoglycaemia | 12 | 17 |
| Documented symptomatic hypoglycaemia | 31 | 6 |
| Probable symptomatic hypoglycaemia | 1 | 2 |
| Pseudo-hypoglycaemia | 30 | 3 |
| Unclassifiable | 4 | 0 |
Severe hypoglycaemia episodes were recorded as per the ISPAD definition. And the following presented hypoglycaemia episodes were recorded as per Novo Nordisk definition: Symptomatic BG-confirmed: An episode that is blood glucose (BG) confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Asymptomatic BG-confirmed: An episode that is BG-confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. 4) Severe or BG-confirmed symptomatic: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. 5) BG-confirmed: An episode that is BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. 6) Severe or BG-confirmed: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia.
| Episodes | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Severe hypoglycaemia | 0 | 0 |
| Asymptomatic BG-confirmed hypoglycaemia | 1 | 1 |
| Symptomatic BG-confirmed hypoglycaemia | 4 | 0 |
| Unclassifiable | 73 | 27 |
This outcome measure is only applicable for the liraglutide 3.0 mg treatment arm. Number of participants who measured with anti-liraglutide binding antibodies at weeks 0, 30, 56, 58, 70 and 82 are presented.
| Participants | Liraglutide 3.0 mg |
|---|---|
| Weeks 0 | 0 |
| Weeks 30 | 6 |
| Weeks 56 | 5 |
| Weeks 58 | 11 |
| Weeks 70 | 6 |
| Weeks 82 | 2 |
Change in pulse was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Beats/minute | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 4 ± 12 | -1 ± 12 |
| Change from week 0 to week 56 | 4 ± 11 | -1 ± 12 |
| Change from week 56 to week 82 | -3 ± 9 | 2 ± 11 |
This outcome measure presents number of subjects with electrocardiogram findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" recorded at baseline (week -14), week 30 and week 56. These findings were categorised by the investigator. Electrocardiogram (ECG) data at week 82 was not collected, thus could not be evaluated. Week 30 and 56 results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.
| Participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Week -14 — Normal | 102 | 100 |
| Week -14 — Abnormal, NCS | 23 | 26 |
| Week -14 — Abnormal, CS | 0 | 0 |
| Week 30 — Normal | 97 | 95 |
| Week 30 — Abnormal, NCS | 20 | 21 |
| Week 30 — Abnormal, CS | 0 | 0 |
| Week 56 — Normal | 83 | 80 |
| Week 56 — Abnormal, NCS | 21 | 23 |
| Week 56 — Abnormal, CS | 0 | 0 |
| Week 82 — Normal | — | — |
| Week 82 — Abnormal, NCS | — | — |
| Week 82 — Abnormal, CS | — | — |
Change in haemoglobin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.2 ± 0.5 | 0.0 ± 0.4 |
| Change from week 0 to week 56 | 0.3 ± 0.6 | 0.1 ± 0.6 |
| Change from week 56 to week 82 | -0.1 ± 0.6 | -0.0 ± 0.4 |
Change in haematocrit was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| % of red blood cells | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.7 ± 2.3 | 0.1 ± 2.4 |
| Change from week 0 to week 56 | 1.2 ± 2.7 | 0.4 ± 2.8 |
| Change from week 56 to week 82 | -0.4 ± 2.9 | -0.4 ± 1.9 |
Change in haematological parameters, "thrombocytes, leucocytes, eosinophils, neutrophils, basophils, lymphocytes and monocytes" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| 10^9 cells/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Thrombocytes: Change from week 0 to week 30 | 9 ± 37 | 14 ± 38 |
| Thrombocytes: Change from week 0 to week 56 | 7 ± 46 | 7 ± 39 |
| Thrombocytes: Change from week 56 to week 82 | -2 ± 31 | 3 ± 37 |
| Leucocytes: Change from week 0 to week 30 | 0.1 ± 1.6 | -0.1 ± 2 |
| Leucocytes: Change from week 0 to week 56 | -0.2 ± 1.6 | -0.4 ± 1.7 |
| Leucocytes: Change from week 56 to week 82 | 0.2 ± 1.5 | 0.0 ± 2.0 |
| Eosinophils: Change from week 0 to week 30 | 0.03 ± 0.15 | 0.04 ± 0.29 |
| Eosinophils: Change from week 0 to week 56 | 0.01 ± 0.15 | 0.00 ± 0.23 |
| Eosinophils: Change from week 56 to week 82 | -0.01 ± 0.12 | 0.00 ± 0.15 |
| Neutrophils: Change from week 0 to week 30 | 0.18 ± 1.33 | -0.01 ± 1.71 |
| Neutrophils: Change from week 0 to week 56 | -0.01 ± 1.49 | -0.13 ± 1.50 |
| Neutrophils: Change from week 56 to week 82 | 0.21 ± 1.35 | -0.00 ± 1.71 |
| Basophils: Change from week 0 to week 30 | 0.01 ± 0.03 | 0.01 ± 0.03 |
| Basophils: Change from week 0 to week 56 | 0.01 ± 0.03 | 0.02 ± 0.03 |
| Basophils: Change from week 56 to week 82 | 0.00 ± 0.03 | 0.00 ± 0.03 |
| Lymphocytes: Change from week 0 to week 30 | -0.18 ± 0.69 | -0.14 ± 0.62 |
| Lymphocytes: Change from week 0 to week 56 | -0.28 ± 0.59 | -0.27 ± 0.72 |
| Lymphocytes: Change from week 56 to week 82 | -0.03 ± 0.48 | -0.00 ± 0.61 |
| Monocytes: Change from week 0 to week 30 | 0.04 ± 0.16 | 0.00 ± 0.18 |
| Monocytes: Change from week 0 to week 56 | 0.06 ± 0.13 | 0.01 ± 0.17 |
| Monocytes: Change from week 56 to week 82 | -0.00 ± 0.15 | 0.04 ± 0.18 |
Change in erythrocytes was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| 10^12 cells/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.0 ± 0.2 | -0.0 ± 0.3 |
| Change from week 0 to week 56 | -0.0 ± 0.3 | -0.1 ± 0.3 |
| Change from week 56 to week 82 | -0.1 ± 0.3 | 0.0 ± 0.2 |
Change in creatinine and bilirubin (total) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| umol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Creatinine: Change from week 0 to week 30 | 1 ± 7 | 0 ± 8 |
| Creatinine: Change from week 0 to week 56 | 2 ± 7 | 4 ± 9 |
| Creatinine: Change from week 56 to week 82 | 2 ± 8 | 1 ± 10 |
| Bilirubin (total): Change from week 0 to week 30 | 1 ± 4 | 1 ± 5 |
| Bilirubin (total): Change from week 0 to week 56 | 1 ± 4 | 1 ± 5 |
| Bilirubin (total): Change from week 56 to week 82 | 0 ± 5 | -0 ± 4 |
Change in biochemistry parameters, "creatinine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| U/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Creatinine kinase: Change from week 0 to week 30 | 13 ± 251 | 0 ± 225 |
| Creatinine kinase: Change from week 0 to week 56 | 32 ± 228 | 0 ± 111 |
| Creatinine kinase: Change from week 56 to week 82 | 28 ± 321 | 4 ± 114 |
| Amylase: Change from week 0 to week 30 | 4 ± 12 | 3 ± 16 |
| Amylase: Change from week 0 to week 56 | 2 ± 10 | -0 ± 9 |
| Amylase: Change from week 56 to week 82 | -1 ± 8 | 1 ± 11 |
| Lipase: Change from week 0 to week 30 | 6 ± 13 | 1 ± 19 |
| Lipase: Change from week 0 to week 56 | 3 ± 13 | -2 ± 5 |
| Lipase: Change from week 56 to week 82 | -4 ± 9 | -0 ± 5 |
| ALT: Change from week 0 to week 30 | -2 ± 15 | -1 ± 15 |
| ALT: Change from week 0 to week 56 | -2 ± 16 | -0 ± 23 |
| ALT: Change from week 56 to week 82 | 1 ± 12 | 2 ± 20 |
| AST: Change from week 0 to week 30 | -1 ± 8 | -1 ± 11 |
| AST: Change from week 0 to week 56 | -1 ± 8 | -1 ± 11 |
| AST: Change from week 56 to week 82 | 1 ± 12 | 1 ± 11 |
| ALP: Change from week 0 to week 30 | -16 ± 25 | -8 ± 66 |
| ALP: Change from week 0 to week 56 | -23 ± 36 | -19 ± 53 |
| ALP: Change from week 56 to week 82 | -2 ± 22 | -10 ± 24 |
Change in biochemistry parameters, "urea (blood urea nitrogen \[BUN\]), sodium, potassium, calcium total and calcium (Ca) albumin-corrected" was evaluated from baseline (week \[Wk\] 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Urea (BUN): Change from week 0 to week 30 | -0.06 ± 1.07 | 0.00 ± 1.14 |
| Urea (BUN): Change from week 0 to week 56 | -0.26 ± 1.01 | -0.05 ± 1.19 |
| Urea (BUN): Change from week 56 to week 82 | 0.23 ± 1.11 | 0.00 ± 1.07 |
| Sodium: Change from week 0 to week 30 | 0 ± 2 | 0 ± 2 |
| Sodium: Change from week 0 to week 56 | 0 ± 2 | 0 ± 3 |
| Sodium: Change from week 56 to week 82 | -1 ± 3 | -1 ± 3 |
| Potassium: Change from week 0 to week 30 | -0.0 ± 0.4 | 0.0 ± 0.3 |
| Potassium: Change from week 0 to week 56 | -0.1 ± 0.4 | -0.0 ± 0.3 |
| Potassium: Change from week 56 to week 82 | 0.0 ± 0.3 | -0.0 ± 0.4 |
| Calcium total: Change from week 0 to week 30 | -0.01 ± 0.09 | -0.03 ± 0.09 |
| Calcium total: Change from week 0 to week 56 | -0.04 ± 0.10 | -0.04 ± 0.09 |
| Calcium total: Change from week 56 to week 82 | -0.00 ± 0.09 | -0.01 ± 0.09 |
| Ca albumin-corrected:Change from week 0 to week 30 | -0.04 ± 0.09 | -0.03 ± 0.09 |
| Ca albumin-corrected:Change from week 0 to week 56 | -0.07 ± 0.10 | -0.07 ± 0.08 |
| Ca albumin-corrected: Change from Wk 56 to Wk 82 | 0.01 ± 0.07 | -0.00 ± 0.09 |
Change in albumin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| g/dL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.1 ± 0.2 | 0.0 ± 0.3 |
| Change from week 0 to week 56 | 0.1 ± 0.3 | 0.1 ± 0.3 |
| Change from week 56 to week 82 | -0.0 ± 0.2 | -0.0 ± 0.3 |
Change in carcinoembryonic antigen (CEA) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| ng/mL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -0.0 ± 0.3 | -0.1 ± 0.6 |
| Change from week 0 to week 56 | 0.0 ± 0.4 | -0.0 ± 0.6 |
| Change from week 56 to week 82 | 0.0 ± 0.4 | 0.0 ± 0.3 |
Change in calcitonin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| ng/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.1 ± 0.8 | 0.1 ± 0.7 |
| Change from week 0 to week 56 | 0.0 ± 0.7 | -0.0 ± 0.8 |
| Change from week 56 to week 82 | -0.1 ± 0.6 | 0.2 ± 1.5 |
Change in hormone levels, "thyroid stimulating hormone (TSH) and prolactin" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| mIU/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| TSH: Change from week 0 to week 30 | -0.35 ± 1.37 | -0.08 ± 1.17 |
| TSH: Change from week 0 to week 56 | -0.42 ± 1.36 | -0.14 ± 1.28 |
| TSH: Change from week 56 to week 82 | 0.38 ± 1.91 | 0.13 ± 1.57 |
| Prolactin: Change from week 0 to week 30 | 23 ± 165 | -47 ± 452 |
| Prolactin: Change from week 0 to week 56 | 63 ± 312 | -63 ± 684 |
| Prolactin: Change from week 56 to week 82 | -29 ± 396 | 13 ± 98 |
Change in hormone levels, "thyroxine (T4) and adrenocorticotropic hormone (ACTH)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| pmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| T4: Change from week 0 to week 30 | 0.6 ± 1.9 | 0.8 ± 2.1 |
| T4: Change from week 0 to week 56 | 0.3 ± 1.8 | 0.6 ± 2.1 |
| T4: Change from week 56 to week 82 | 0.0 ± 1.6 | 0.2 ± 2.3 |
| ACTH: Change from week 0 to week 30 | 0.4 ± 4.4 | 0.5 ± 3.9 |
| ACTH: Change from week 0 to week 56 | 0.6 ± 4.9 | 0.6 ± 3.8 |
| ACTH: Change from week 56 to week 82 | -0.8 ± 4.7 | -0.4 ± 2.9 |
Change in hormone levels, "insulin-like growth factor-1 (IGF-1) and cortisol" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| ng/mL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| IGF-1: Change from week 0 to week 30 | 10.61 ± 89.83 | 3.79 ± 101.12 |
| IGF-1: Change from week 0 to week 56 | -4.60 ± 84.51 | 3.69 ± 111.63 |
| IGF-1: Change from week 56 to week 82 | -14.60 ± 80.82 | -16.35 ± 65.89 |
| Cortisol: Change from week 0 to week 30 | 6.9 ± 66.9 | 8.6 ± 60.1 |
| Cortisol: Change from week 0 to week 56 | 5.1 ± 65.2 | 8.5 ± 57.9 |
| Cortisol: Change from week 56 to week 82 | 0.6 ± 66.6 | 10.4 ± 61.2 |
Change in dehydroepiandrosterone sulfate (DHEAS) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| umol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.94 ± 1.66 | 0.57 ± 1.78 |
| Change from week 0 to week 56 | 0.95 ± 1.91 | 0.89 ± 2.05 |
| Change from week 56 to week 82 | -0.08 ± 2.11 | -0.05 ± 1.27 |
Change in hormone levels, "luteinising hormone (LH) and follicle stimulating hormone (FSH)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| IU/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| LH: Change from week 0 to week 30 | 0.4 ± 9.1 | 0.7 ± 7.9 |
| LH: Change from week 0 to week 56 | 0.2 ± 9.1 | 0.6 ± 6.6 |
| LH: Change from week 56 to week 82 | 0.4 ± 8.7 | -0.5 ± 8.0 |
| FSH: Change from week 0 to week 30 | 0.2 ± 2.6 | -0.2 ± 2.7 |
| FSH: Change from week 0 to week 56 | 0.6 ± 4.0 | 0.1 ± 2.5 |
| FSH: Change from week 56 to week 82 | -0.1 ± 3.6 | -0.1 ± 3.1 |
Change in estradiol (only for female) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| pg/mL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -5.0 ± 81.0 | 20.2 ± 67.6 |
| Change from week 0 to week 56 | 11.6 ± 94.4 | 14.1 ± 63.6 |
| Change from week 56 to week 82 | -2.3 ± 89.1 | -1.7 ± 65.3 |
This outcome measure presents "testosterone (only for males) results" for baseline (week 0), week 30, week 56 and week 82. ADVIA Centaur Testosterone (TSTO) assay was used for the evaluation of testosterone hormone. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| nmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Week 0 | 8.13 ± 3.45 | 8.06 ± 3.66 |
| Week 30 | 10.00 ± 4.02 | 9.33 ± 5.27 |
| Week 56 | 10.55 ± 4.14 | 9.51 ± 3.31 |
| Week 82 | 11.36 ± 5.27 | 6.16 ± 3.27 |
Change in type I collagen N-telopeptide (NTX1) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are presented in "nmol bone collagen equivalents (BCE)/L". Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| nmol BCE/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -2.4 ± 10.4 | -3.2 ± 12.0 |
| Change from week 0 to week 56 | -3.7 ± 14.1 | -2.9 ± 15.1 |
| Change from week 56 to week 82 | -2.8 ± 12.8 | -4.6 ± 10.0 |
Change in type I collagen C-telopeptide (CTX1) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| pg/mL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -7 ± 358 | -84 ± 404 |
| Change from week 0 to week 56 | -36 ± 353 | -97 ± 473 |
| Change from week 56 to week 82 | -107 ± 359 | -162 ± 318 |
Change in procollagen 1 N-terminal propeptide (P1NP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| ng/mL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -35 ± 124 | -30 ± 184 |
| Change from week 0 to week 56 | -55 ± 151 | -63 ± 192 |
| Change from week 56 to week 82 | -30 ± 107 | -47 ± 84 |
Change in alkaline phosphatase (bone specific) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| U/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -15 ± 16 | -12 ± 26 |
| Change from week 0 to week 56 | -17 ± 18 | -17 ± 30 |
| Change from week 56 to week 82 | -1 ± 11 | -4 ± 12 |
This outcome measure presents "pubertal status results" which is based on Tanner staging (Tanner stage 2-5), recorded at baseline (week 0), week 30, week 56 and week 82. Results are presented for the following categories: 1) For female: breast development and pubic hair development (by Tanner staging). 2) For male: penis development and pubic hair development (by Tanner staging). Each category shows number of participants in stages 2 to 5, where stage 2 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult". Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Week 0: Breast development (for female) — Stage 2 | 2 | 1 |
| Week 0: Breast development (for female) — Stage 3 | 6 | 8 |
| Week 0: Breast development (for female) — Stage 4 | 23 | 30 |
| Week 0: Breast development (for female) — Stage 5 | 40 | 39 |
| Week 30: Breast development (for female) — Stage 2 | 1 | 0 |
| Week 30: Breast development (for female) — Stage 3 | 4 | 6 |
| Week 30: Breast development (for female) — Stage 4 | 22 | 25 |
| Week 30: Breast development (for female) — Stage 5 | 39 | 43 |
| Week 56: Breast development (for female) — Stage 2 | 0 | 0 |
| Week 56: Breast development (for female) — Stage 3 | 2 | 2 |
| Week 56: Breast development (for female) — Stage 4 | 14 | 20 |
| Week 56: Breast development (for female) — Stage 5 | 41 | 41 |
| Week 82: Breast development (for female) — Stage 2 | 0 | 0 |
| Week 82: Breast development (for female) — Stage 3 | 0 | 2 |
| Week 82: Breast development (for female) — Stage 4 | 7 | 13 |
| Week 82: Breast development (for female) — Stage 5 | 46 | 46 |
| Week 0: Pubic hair development (for female) — Stage 2 | 2 | 3 |
| Week 0: Pubic hair development (for female) — Stage 3 | 6 | 5 |
| Week 0: Pubic hair development (for female) — Stage 4 | 22 | 26 |
| Week 0: Pubic hair development (for female) — Stage 5 | 41 | 44 |
| Week 30: Pubic hair development (for female) — Stage 2 | 1 | 0 |
| Week 30: Pubic hair development (for female) — Stage 3 | 4 | 4 |
| Week 30: Pubic hair development (for female) — Stage 4 | 20 | 25 |
| Week 30: Pubic hair development (for female) — Stage 5 | 41 | 45 |
| Week 56: Pubic hair development (for female) — Stage 2 | 1 | 0 |
| Week 56: Pubic hair development (for female) — Stage 3 | 2 | 2 |
| Week 56: Pubic hair development (for female) — Stage 4 | 13 | 21 |
| Week 56: Pubic hair development (for female) — Stage 5 | 41 | 40 |
| Week 82: Pubic hair development (for female) — Stage 2 | 0 | 0 |
| Week 82: Pubic hair development (for female) — Stage 3 | 1 | 2 |
| Week 82: Pubic hair development (for female) — Stage 4 | 7 | 14 |
| Week 82: Pubic hair development (for female) — Stage 5 | 45 | 45 |
| Week 0: penis development (male) — Stage 2 | 4 | 7 |
| Week 0: penis development (male) — Stage 3 | 11 | 8 |
| Week 0: penis development (male) — Stage 4 | 16 | 14 |
| Week 0: penis development (male) — Stage 5 | 23 | 19 |
| Week 30: penis development (male) — Stage 2 | 1 | 2 |
| Week 30: penis development (male) — Stage 3 | 11 | 7 |
| Week 30: penis development (male) — Stage 4 | 14 | 11 |
| Week 30: penis development (male) — Stage 5 | 25 | 25 |
| Week 56: penis development (male) — Stage 2 | 1 | 0 |
| Week 56: penis development (male) — Stage 3 | 6 | 6 |
| Week 56: penis development (male) — Stage 4 | 15 | 6 |
| Week 56: penis development (male) — Stage 5 | 26 | 29 |
| Week 82: penis development (male) — Stage 2 | 0 | 0 |
| Week 82: penis development (male) — Stage 3 | 3 | 3 |
| Week 82: penis development (male) — Stage 4 | 11 | 6 |
| Week 82: penis development (male) — Stage 5 | 31 | 29 |
| Week 0: Pubic hair development (male) — Stage 2 | 6 | 9 |
| Week 0: Pubic hair development (male) — Stage 3 | 8 | 5 |
| Week 0: Pubic hair development (male) — Stage 4 | 19 | 13 |
| Week 0: Pubic hair development (male) — Stage 5 | 21 | 21 |
| Week 30: Pubic hair development (male) — Stage 2 | 1 | 3 |
| Week 30: Pubic hair development (male) — Stage 3 | 10 | 7 |
| Week 30: Pubic hair development (male) — Stage 4 | 15 | 9 |
| Week 30: Pubic hair development (male) — Stage 5 | 24 | 26 |
| Week 56: Pubic hair development (male) — Stage 2 | 1 | 0 |
| Week 56: Pubic hair development (male) — Stage 3 | 7 | 6 |
| Week 56: Pubic hair development (male) — Stage 4 | 15 | 7 |
| Week 56: Pubic hair development (male) — Stage 5 | 24 | 28 |
| Week 82: Pubic hair development (male) — Stage 2 | 0 | 0 |
| Week 82: Pubic hair development (male) — Stage 3 | 3 | 2 |
| Week 82: Pubic hair development (male) — Stage 4 | 10 | 8 |
| Week 82: Pubic hair development (male) — Stage 5 | 30 | 28 |
This outcome measure presents number of subjects with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 30, week 56 and week 82. These findings were categorised by the investigator. Results include examination of: "general appearance"; "head, ears, eyes, nose, throat, neck"; "respiratory system"; "cardiovascular system (CVS)"; "gastrointestinal (GI) system including mouth"; "musculoskeletal system"; "central nervous system (CNS) and peripheral nervous system (PNS)"; "skin"; "thyroid gland" and "lymph node palpation". Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| General Appearance: Week 0 — Normal | 93 | 101 |
| General Appearance: Week 0 — Abnormal, NCS | 30 | 23 |
| General Appearance: Week 0 — Abnormal, CS | 2 | 2 |
| General Appearance: Week 30 — Normal | 94 | 95 |
| General Appearance: Week 30 — Abnormal, NCS | 21 | 20 |
| General Appearance: Week 30 — Abnormal, CS | 1 | 1 |
| General Appearance: Week 56 — Normal | 84 | 85 |
| General Appearance: Week 56 — Abnormal, NCS | 18 | 16 |
| General Appearance: Week 56 — Abnormal, CS | 2 | 1 |
| General Appearance: Week 82 — Normal | 80 | 81 |
| General Appearance: Week 82 — Abnormal, NCS | 18 | 17 |
| General Appearance: Week 82 — Abnormal, CS | 1 | 1 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Normal | 120 | 116 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, NCS | 5 | 10 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, CS | 0 | 0 |
| Head, ears, eyes, nose, throat, neck: Week 30 — Normal | 114 | 107 |
| Head, ears, eyes, nose, throat, neck: Week 30 — Abnormal, NCS | 2 | 9 |
| Head, ears, eyes, nose, throat, neck: Week 30 — Abnormal, CS | 0 | 0 |
| Head, ears, eyes, nose, throat, neck: Week 56 — Normal | 101 | 98 |
| Head, ears, eyes, nose, throat, neck: Week 56 — Abnormal, NCS | 3 | 4 |
| Head, ears, eyes, nose, throat, neck: Week 56 — Abnormal, CS | 0 | 0 |
| Head, ears, eyes, nose, throat, neck: Week 82 — Normal | 98 | 94 |
| Head, ears, eyes, nose, throat, neck: Week 82 — Abnormal, NCS | 1 | 5 |
| Head, ears, eyes, nose, throat, neck: Week 82 — Abnormal, CS | 0 | 0 |
| Respiratory system: Week 0 — Normal | 125 | 123 |
| Respiratory system: Week 0 — Abnormal, NCS | 0 | 3 |
| Respiratory system: Week 0 — Abnormal, CS | 0 | 0 |
| Respiratory system: Week 30 — Normal | 116 | 115 |
| Respiratory system: Week 30 — Abnormal, NCS | 0 | 1 |
| Respiratory system: Week 30 — Abnormal, CS | 0 | 0 |
| Respiratory system: Week 56 — Normal | 104 | 101 |
| Respiratory system: Week 56 — Abnormal, NCS | 0 | 1 |
| Respiratory system: Week 56 — Abnormal, CS | 0 | 0 |
| Respiratory system: Week 82 — Normal | 99 | 96 |
| Respiratory system: Week 82 — Abnormal, NCS | 0 | 3 |
| Respiratory system: Week 82 — Abnormal, CS | 0 | 0 |
| Cardiovascular system: Week 0 — Normal | 124 | 125 |
| Cardiovascular system: Week 0 — Abnormal, NCS | 1 | 1 |
| Cardiovascular system: Week 0 — Abnormal, CS | 0 | 0 |
| Cardiovascular system: Week 30 — Normal | 115 | 112 |
| Cardiovascular system: Week 30 — Abnormal, NCS | 1 | 4 |
| Cardiovascular system: Week 30 — Abnormal, CS | 0 | 0 |
| Cardiovascular system: Week 56 — Normal | 102 | 100 |
| Cardiovascular system: Week 56 — Abnormal, NCS | 2 | 2 |
| Cardiovascular system: Week 56 — Abnormal, CS | 0 | 0 |
| Cardiovascular system: Week 82 — Normal | 97 | 98 |
| Cardiovascular system: Week 82 — Abnormal, NCS | 2 | 1 |
| Cardiovascular system: Week 82 — Abnormal, CS | 0 | 0 |
| GI system including mouth: Week 0 — Normal | 119 | 119 |
| GI system including mouth: Week 0 — Abnormal, NCS | 5 | 6 |
| GI system including mouth: Week 0 — Abnormal, CS | 1 | 1 |
| GI system including mouth: Week 30 — Normal | 111 | 109 |
| GI system including mouth: Week 30 — Abnormal, NCS | 5 | 6 |
| GI system including mouth: Week 30 — Abnormal, CS | 0 | 1 |
| GI system including mouth: Week 56 — Normal | 102 | 98 |
| GI system including mouth: Week 56 — Abnormal, NCS | 2 | 4 |
| GI system including mouth: Week 56 — Abnormal, CS | 0 | 0 |
| GI system including mouth: Week 82 — Normal | 96 | 94 |
| GI system including mouth: Week 82 — Abnormal, NCS | 1 | 5 |
| GI system including mouth: Week 82 — Abnormal, CS | 2 | 0 |
| Musculoskeletal system: Week 0 — Normal | 121 | 119 |
| Musculoskeletal system: Week 0 — Abnormal, NCS | 4 | 7 |
| Musculoskeletal system: Week 0 — Abnormal, CS | 0 | 0 |
| Musculoskeletal system: Week 30 — Normal | 113 | 106 |
| Musculoskeletal system: Week 30 — Abnormal, NCS | 3 | 10 |
| Musculoskeletal system: Week 30 — Abnormal, CS | 0 | 0 |
| Musculoskeletal system: Week 56 — Normal | 102 | 97 |
| Musculoskeletal system: Week 56 — Abnormal, NCS | 1 | 5 |
| Musculoskeletal system: Week 56 — Abnormal, CS | 1 | 0 |
| Musculoskeletal system: Week 82 — Normal | 97 | 92 |
| Musculoskeletal system: Week 82 — Abnormal, NCS | 1 | 7 |
| Musculoskeletal system: Week 82 — Abnormal, CS | 1 | 0 |
| CNS and PNS: Week 0 — Normal | 124 | 124 |
| CNS and PNS: Week 0 — Abnormal, NCS | 1 | 2 |
| CNS and PNS: Week 0 — Abnormal, CS | 0 | 0 |
| CNS and PNS: Week 30 — Normal | 115 | 115 |
| CNS and PNS: Week 30 — Abnormal, NCS | 1 | 1 |
| CNS and PNS: Week 30 — Abnormal, CS | 0 | 0 |
| CNS and PNS: Week 56 — Normal | 104 | 101 |
| CNS and PNS: Week 56 — Abnormal, NCS | 0 | 1 |
| CNS and PNS: Week 56 — Abnormal, CS | 0 | 0 |
| CNS and PNS: Week 82 — Normal | 99 | 98 |
| CNS and PNS: Week 82 — Abnormal, NCS | 0 | 1 |
| CNS and PNS: Week 82 — Abnormal, CS | 0 | 0 |
| Skin: Week 0 — Normal | 76 | 58 |
| Skin: Week 0 — Abnormal, NCS | 47 | 64 |
| Skin: Week 0 — Abnormal, CS | 2 | 4 |
| Skin: Week 30 — Normal | 71 | 56 |
| Skin: Week 30 — Abnormal, NCS | 44 | 56 |
| Skin: Week 30 — Abnormal, CS | 1 | 4 |
| Skin: Week 56 — Normal | 65 | 48 |
| Skin: Week 56 — Abnormal, NCS | 35 | 53 |
| Skin: Week 56 — Abnormal, CS | 4 | 1 |
| Skin: Week 82 — Normal | 57 | 50 |
| Skin: Week 82 — Abnormal, NCS | 40 | 48 |
| Skin: Week 82 — Abnormal, CS | 2 | 1 |
| Thyroid gland: Week 0 — Normal | 124 | 124 |
| Thyroid gland: Week 0 — Abnormal, NCS | 1 | 2 |
| Thyroid gland: Week 0 — Abnormal, CS | 0 | 0 |
| Thyroid gland: Week 30 — Normal | 115 | 114 |
| Thyroid gland: Week 30 — Abnormal, NCS | 1 | 2 |
| Thyroid gland: Week 30 — Abnormal, CS | 0 | 0 |
| Thyroid gland: Week 56 — Normal | 103 | 101 |
| Thyroid gland: Week 56 — Abnormal, NCS | 1 | 1 |
| Thyroid gland: Week 56 — Abnormal, CS | 0 | 0 |
| Thyroid gland: Week 82 — Normal | 97 | 98 |
| Thyroid gland: Week 82 — Abnormal, NCS | 2 | 1 |
| Thyroid gland: Week 82 — Abnormal, CS | 0 | 0 |
| Lymph node palpation: Week 0 — Normal | 124 | 125 |
| Lymph node palpation: Week 0 — Abnormal, NCS | 1 | 1 |
| Lymph node palpation: Week 0 — Abnormal, CS | 0 | 0 |
| Lymph node palpation: Week 30 — Normal | 115 | 116 |
| Lymph node palpation: Week 30 — Abnormal, NCS | 1 | 0 |
| Lymph node palpation: Week 30 — Abnormal, CS | 0 | 0 |
| Lymph node palpation: Week 56 — Normal | 103 | 102 |
| Lymph node palpation: Week 56 — Abnormal, NCS | 1 | 0 |
| Lymph node palpation: Week 56 — Abnormal, CS | 0 | 0 |
| Lymph node palpation: Week 82 — Normal | 98 | 98 |
| Lymph node palpation: Week 82 — Abnormal, NCS | 1 | 1 |
| Lymph node palpation: Week 82 — Abnormal, CS | 0 | 0 |
Change in height standard deviation score (SDS) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.
| SDS | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | 0.11 ± 0.17 | 0.13 ± 0.18 |
| Change from week 0 to week 56 | 0.20 ± 0.27 | 0.24 ± 0.30 |
| Change from week 56 to week 82 | 0.07 ± 0.16 | 0.06 ± 0.12 |
This outcome measure presents number of subjects with "suicidal ideation or suicidal behaviour on the Columbia Suicidality Severity Rating Scale (C-SSRS)" assessed at baseline (week 0), week 30, week 56 and week 82. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Wk 0: Suicidal ideation | 2 | 2 |
| Wk 0: Suicidal behaviour | 0 | 1 |
| Wk0: Self-injurious behaviour, no suicidal intent | 0 | 1 |
| Wk 30: Suicidal ideation | 0 | 0 |
| Wk 30: Suicidal behaviour | 0 | 0 |
| Wk30: Self-injurious behaviour, no suicidal intent | 0 | 0 |
| Wk 56: Suicidal ideation | 0 | 0 |
| Wk 56: Suicidal behaviour | 0 | 0 |
| Wk56: Self-injurious behaviour, no suicidal intent | 0 | 0 |
| Wk 82: Suicidal ideation | 0 | 0 |
| Wk 82: Suicidal behaviour | 0 | 0 |
| Wk82: Self-injurious behaviour, no suicidal intent | 0 | 0 |
Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change from week 0 to week 30 | -1 ± 4 | -1 ± 4 |
| Change from week 0 to week 56 | -1 ± 3 | -2 ± 3 |
| Change from week 56 to week 82 | 0 ± 2 | -0 ± 3 |
Collected over Week 0-56 + 14 days. Results are based on the SAS which included all randomised participants exposed to at least one dose of trial product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 3.0 mg | 1/125 (0.8%) | 3/125 (2.4%) | 100/125 (80%) |
| Placebo | 0/126 (0%) | 5/126 (4%) | 84/126 (66.7%) |
| Event | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Completed suicidePsychiatric disorders | 1/125 | 0/126 |
| MyositisMusculoskeletal and connective tissue disorders | 1/125 | 0/126 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/125 | 0/126 |
| AppendicitisInfections and infestations | 0/125 | 1/126 |
| Cholecystitis acuteHepatobiliary disorders | 0/125 | 1/126 |
| CholelithiasisHepatobiliary disorders | 0/125 | 1/126 |
| Haemorrhagic ovarian cystReproductive system and breast disorders | 0/125 | 1/126 |
| PneumoniaInfections and infestations | 0/125 | 1/126 |
| ThrombophlebitisVascular disorders | 0/125 | 1/126 |
| Event | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 53/125 | 18/126 |
| VomitingGastrointestinal disorders | 43/125 | 5/126 |
| NasopharyngitisInfections and infestations | 34/125 | 38/126 |
| HeadacheNervous system disorders | 29/125 | 35/126 |
| DiarrhoeaGastrointestinal disorders | 28/125 | 18/126 |
| Abdominal pain upperGastrointestinal disorders | 17/125 | 17/126 |
| GastroenteritisInfections and infestations | 16/125 | 6/126 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 11/125 | 15/126 |
| DizzinessNervous system disorders | 13/125 | 4/126 |
| InfluenzaInfections and infestations | 11/125 | 12/126 |
Results are based on the full analysis set (FAS) which included all randomised participants who had received at least one dose of trial product and had any post-randomisation data (according to the intention-to-treat \[ITT\] principle).
| Age, Continuous(Years) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 14.6 ± 1.6 | 14.5 ± 1.6 | 14.5 ± 1.6 |
| Sex: Female, Male(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Female | 71 | 78 | 149 |
| Male | 54 | 48 | 102 |
| Ethnicity (NIH/OMB)(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 24 | 56 |
| Not Hispanic or Latino | 93 | 102 | 195 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 0 | 2 |
| Black or African American | 14 | 6 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 105 | 115 | 220 |
| Other | 4 | 4 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Feb 2019, 28 months.
Results were first posted in Apr 2020, 1 year 2 months after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 28 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide